BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosen BH, Chanson M, Gawenis LR, Liu J, Sofoluwe A, Zoso A, Engelhardt JF. Animal and model systems for studying cystic fibrosis. J Cyst Fibros 2018;17:S28-34. [PMID: 28939349 DOI: 10.1016/j.jcf.2017.09.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Fortune AJ, Fletcher JL, Blackburn NB, Young KM. Using MS induced pluripotent stem cells to investigate MS aetiology. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103839] [Reference Citation Analysis]
2 McCarron A, Parsons D, Donnelley M. Animal and Cell Culture Models for Cystic Fibrosis: Which Model Is Right for Your Application? Am J Pathol 2021;191:228-42. [PMID: 33232694 DOI: 10.1016/j.ajpath.2020.10.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Rao MC. Physiology of Electrolyte Transport in the Gut: Implications for Disease. Compr Physiol 2019;9:947-1023. [PMID: 31187895 DOI: 10.1002/cphy.c180011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Castellani S, Di Gioia S, di Toma L, Conese M. Human Cellular Models for the Investigation of Lung Inflammation and Mucus Production in Cystic Fibrosis. Anal Cell Pathol (Amst) 2018;2018:3839803. [PMID: 30581723 DOI: 10.1155/2018/3839803] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
5 Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochim Biophys Acta Mol Basis Dis 2019;1865:965-9. [PMID: 30071276 DOI: 10.1016/j.bbadis.2018.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Callebaut I, Mense M, Farinha CM. Exploring the basic mechanisms in Cystic Fibrosis: Promoting data presentation and discussion at the 16th ECFS Basic Science Conference. J Cyst Fibros 2020;19 Suppl 1:S1-4. [PMID: 31932104 DOI: 10.1016/j.jcf.2019.12.013] [Reference Citation Analysis]
7 Guan S, Munder A, Hedtfeld S, Braubach P, Glage S, Zhang L, Lienenklaus S, Schultze A, Hasenpusch G, Garrels W, Stanke F, Miskey C, Johler SM, Kumar Y, Tümmler B, Rudolph C, Ivics Z, Rosenecker J. Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol 2019;14:287-97. [DOI: 10.1038/s41565-018-0358-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
8 Leenaars CH, Vries RB, Reijmer J, Holthaus D, Visser D, Heming A, Elzinga J, Kempkes RW, Beumer W, Punt C, Meijboom FL, Ritskes-Hoitinga M. Animal models for cystic fibrosis: a systematic search and mapping review of the literature. Part 2: nongenetic models. Lab Anim 2021;55:307-16. [PMID: 33557683 DOI: 10.1177/0023677221990688] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wine JJ. How to live a long and healthy life with cystic fibrosis: Lessons from the CF ferret. J Cyst Fibros 2019;18:8-9. [PMID: 30361142 DOI: 10.1016/j.jcf.2018.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Fakıoğlu DM, Altun B. New Therapeutic Approaches in Cystic Fibrosis. Turk J Pharm Sci 2020;17:686-97. [PMID: 33389985 DOI: 10.4274/tjps.galenos.2020.76401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Mergiotti M, Murabito A, Prono G, Ghigo A. CFTR Modulator Therapy for Rare CFTR Mutants. JoR 2022;2:59-76. [DOI: 10.3390/jor2020005] [Reference Citation Analysis]
12 Conte G, Costabile G, Baldassi D, Rondelli V, Bassi R, Colombo D, Linardos G, Fiscarelli EV, Sorrentino R, Miro A, Quaglia F, Brocca P, d'Angelo I, Merkel OM, Ungaro F. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference? ACS Appl Mater Interfaces 2022;14:7565-78. [PMID: 35107987 DOI: 10.1021/acsami.1c14975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ling KM, Garratt LW, Lassmann T, Stick SM, Kicic A; WAERP., AusREC., Australian Respiratory Early Surveillance Team for Cystic Fibrosis. Elucidating the Interaction of CF Airway Epithelial Cells and Rhinovirus: Using the Host-Pathogen Relationship to Identify Future Therapeutic Strategies. Front Pharmacol 2018;9:1270. [PMID: 30464745 DOI: 10.3389/fphar.2018.01270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Rosen BH, Evans TIA, Moll SR, Gray JS, Liang B, Sun X, Zhang Y, Jensen-Cody CW, Swatek AM, Zhou W, He N, Rotti PG, Tyler SR, Keiser NW, Anderson PJ, Brooks L, Li Y, Pope RM, Rajput M, Hoffman EA, Wang K, Harris JK, Parekh KR, Gibson-Corley KN, Engelhardt JF. Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets. Am J Respir Crit Care Med 2018;197:1308-18. [PMID: 29327941 DOI: 10.1164/rccm.201708-1616OC] [Cited by in Crossref: 68] [Cited by in F6Publishing: 43] [Article Influence: 22.7] [Reference Citation Analysis]
15 Shi J, Li H, Yuan C, Luo M, Wei J, Liu X. Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Oxid Med Cell Longev. 2018;2018:6567578. [PMID: 29849907 DOI: 10.1155/2018/6567578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Bose SJ, Krainer G, Ng DRS, Schenkel M, Shishido H, Yoon JS, Haggie PM, Schlierf M, Sheppard DN, Skach WR. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR. J Cyst Fibros 2020;19 Suppl 1:S25-32. [PMID: 31902693 DOI: 10.1016/j.jcf.2019.12.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Turton KB, Ingram RJ, Valvano MA. Macrophage dysfunction in cystic fibrosis: Nature or nurture? J Leukoc Biol 2021;109:573-82. [PMID: 32678926 DOI: 10.1002/JLB.4RU0620-245R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Birket SE, Davis JM, Fernandez-Petty CM, Henderson AG, Oden AM, Tang L, Wen H, Hong J, Fu L, Chambers A, Fields A, Zhao G, Tearney GJ, Sorscher EJ, Rowe SM. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR. Am J Respir Crit Care Med 2020;202:1271-82. [PMID: 32584141 DOI: 10.1164/rccm.202002-0369OC] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Maule G, Arosio D, Cereseto A. Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing. Int J Mol Sci 2020;21:E3903. [PMID: 32486152 DOI: 10.3390/ijms21113903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
20 Bonfield TL. Preclinical Modeling for Therapeutic Development in Cystic Fibrosis. Am J Respir Crit Care Med 2020;201:267-8. [PMID: 31697560 DOI: 10.1164/rccm.201910-2056ED] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hisert KB. Rats Race to Keep Pace in the Growing Cystic Fibrosis Model Space. Am J Respir Crit Care Med 2020;202:1212-4. [PMID: 32692578 DOI: 10.1164/rccm.202006-2330ED] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Laucirica DR, Garratt LW, Kicic A. Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity. Front Immunol 2020;11:595. [PMID: 32318073 DOI: 10.3389/fimmu.2020.00595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lee JA, Cho A, Huang EN, Xu Y, Quach H, Hu J, Wong AP. Gene therapy for cystic fibrosis: new tools for precision medicine. J Transl Med 2021;19:452. [PMID: 34717671 DOI: 10.1186/s12967-021-03099-4] [Reference Citation Analysis]
24 Strandvik B, O Neal WK, Ali MA, Hammar U. Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice. Exp Biol Med (Maywood) 2018;243:496-503. [PMID: 29513100 DOI: 10.1177/1535370218758605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Baldassi D, Gabold B, Merkel O. Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions. Adv Nanobiomed Res 2021;1:2000111. [PMID: 34345878 DOI: 10.1002/anbr.202000111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Shei RJ, Peabody JE, Kaza N, Rowe SM. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 2018;43:152-65. [PMID: 30340955 DOI: 10.1016/j.coph.2018.09.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
27 Ghanem R, Laurent V, Roquefort P, Haute T, Ramel S, Le Gall T, Aubry T, Montier T. Optimizations of In Vitro Mucus and Cell Culture Models to Better Predict In Vivo Gene Transfer in Pathological Lung Respiratory Airways: Cystic Fibrosis as an Example. Pharmaceutics 2020;13:47. [PMID: 33396283 DOI: 10.3390/pharmaceutics13010047] [Reference Citation Analysis]
28 Dreano E, Bacchetta M, Simonin J, Galmiche L, Usal C, Slimani L, Sadoine J, Tesson L, Anegon I, Concordet JP, Hatton A, Vignaud L, Tondelier D, Sermet-Gaudelus I, Chanson M, Cottart CH. Characterization of two rat models of cystic fibrosis-KO and F508del CFTR-Generated by Crispr-Cas9. Animal Model Exp Med 2019;2:297-311. [PMID: 31942562 DOI: 10.1002/ame2.12091] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
29 Moses C, Kaur P. Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing. Respirology 2019;24:628-37. [PMID: 30883991 DOI: 10.1111/resp.13527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Brevini T, Tysoe OC, Sampaziotis F. Tissue engineering of the biliary tract and modelling of cholestatic disorders. Journal of Hepatology 2020;73:918-32. [DOI: 10.1016/j.jhep.2020.05.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Froux L, Billet A, Becq F. Modulating the cystic fibrosis transmembrane regulator and the development of new precision drugs. Expert Review of Precision Medicine and Drug Development 2018;3:357-70. [DOI: 10.1080/23808993.2018.1547109] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Belgacemi R, Luczka E, Ancel J, Diabasana Z, Perotin JM, Germain A, Lalun N, Birembaut P, Dubernard X, Mérol JC, Delepine G, Polette M, Deslée G, Dormoy V. Airway epithelial cell differentiation relies on deficient Hedgehog signalling in COPD. EBioMedicine 2020;51:102572. [PMID: 31877414 DOI: 10.1016/j.ebiom.2019.11.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
33 Okuda K, Randell SH, Birket SE. The Big Impact of Small Airway pH. Am J Respir Cell Mol Biol 2021;65:123-5. [PMID: 33831321 DOI: 10.1165/rcmb.2021-0070ED] [Reference Citation Analysis]
34 Yan Z, McCray PB Jr, Engelhardt JF. Advances in gene therapy for cystic fibrosis lung disease. Hum Mol Genet 2019;28:R88-94. [PMID: 31332440 DOI: 10.1093/hmg/ddz139] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
35 O'Brien TJ, Welch M. Recapitulation of polymicrobial communities associated with cystic fibrosis airway infections: a perspective. Future Microbiol 2019;14:1437-50. [PMID: 31778075 DOI: 10.2217/fmb-2019-0200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
36 Cabral B, Terlizzi V, Laselva O, Conte Filho C, Mota F. Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers. JCM 2022;11:1283. [DOI: 10.3390/jcm11051283] [Reference Citation Analysis]
37 Ensinck M, Mottais A, Detry C, Leal T, Carlon MS. On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis. Front Pharmacol 2021;12:662110. [PMID: 33986686 DOI: 10.3389/fphar.2021.662110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
39 Viotti Perisse I, Fan Z, Van Wettere A, Liu Y, Leir SH, Keim J, Regouski M, Wilson MD, Cholewa KM, Mansbach SN, Kelley TJ, Wang Z, Harris A, White KL, Polejaeva IA. Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics. FASEB Bioadv 2021;3:841-54. [PMID: 34632318 DOI: 10.1096/fba.2021-00043] [Reference Citation Analysis]
40 Di Fulvio M, Bogdani M, Velasco M, McMillen TS, Ridaura C, Kelly L, Almutairi MM, Kursan S, Sajib AA, Hiriart M, Aguilar-Bryan L. Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet. PLoS One 2020;15:e0242749. [PMID: 33264332 DOI: 10.1371/journal.pone.0242749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Pallottini V, Pfrieger FW. Understanding and Treating Niemann-Pick Type C Disease: Models Matter. Int J Mol Sci 2020;21:E8979. [PMID: 33256121 DOI: 10.3390/ijms21238979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Xu J, Livraghi-Butrico A, Hou X, Rajagopalan C, Zhang J, Song J, Jiang H, Wei HG, Wang H, Bouhamdan M, Ruan J, Yang D, Qiu Y, Xie Y, Barrett R, McClellan S, Mou H, Wu Q, Chen X, Rogers TD, Wilkinson KJ, Gilmore RC, Esther CR Jr, Zaman K, Liang X, Sobolic M, Hazlett L, Zhang K, Frizzell RA, Gentzsch M, O'Neal WK, Grubb BR, Chen YE, Boucher RC, Sun F. Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene. JCI Insight 2021;6:139813. [PMID: 33232302 DOI: 10.1172/jci.insight.139813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Grubb BR, Livraghi-butrico A. Animal models of cystic fibrosis in the era of highly effective modulator therapies. Current Opinion in Pharmacology 2022;64:102235. [DOI: 10.1016/j.coph.2022.102235] [Reference Citation Analysis]
44 Cabrini G. Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure. Mol Diagn Ther 2019;23:263-79. [PMID: 30478715 DOI: 10.1007/s40291-018-0372-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
45 Green M, Lindgren N, Henderson A, Keith JD, Oden AM, Birket SE. Ivacaftor partially corrects airway inflammation in a humanized G551D rat. Am J Physiol Lung Cell Mol Physiol 2021;320:L1093-100. [PMID: 33825507 DOI: 10.1152/ajplung.00082.2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Tam PKH, Yiu RS, Lendahl U, Andersson ER. Cholangiopathies - Towards a molecular understanding. EBioMedicine 2018;35:381-93. [PMID: 30236451 DOI: 10.1016/j.ebiom.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
47 Ideozu JE, Zhang X, McColley S, Levy H. Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. Genes (Basel) 2019;10:E180. [PMID: 30813620 DOI: 10.3390/genes10030180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
48 Lane MC, Gordon JL, Jiang C, Leitner WW, Pickett TE, Stemmy E, Bozick BA, Deckhut-Augustine A, Embry AC, Post DJ. Workshop report: Optimization of animal models to better predict influenza vaccine efficacy. Vaccine 2020;38:2751-7. [PMID: 32145879 DOI: 10.1016/j.vaccine.2020.01.101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kim MD, Baumlin N, Yoshida M, Polineni D, Salathe SF, David JK, Peloquin CA, Wanner A, Dennis JS, Sailland J, Whitney P, Horrigan FT, Sabater JR, Abraham WM, Salathe M. Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. Am J Respir Crit Care Med 2020;201:313-24. [PMID: 31613648 DOI: 10.1164/rccm.201905-0990OC] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]